Retatrutide doesn't have a price yet. Here's where every number comes from

The short answer: retatrutide doesn't cost anything yet, because it isn't for sale. Not legally, anyway.

Eli Lilly hasn't filed it with the FDA, so there's no list price, no pharmacy price and no insurance price. Every number you've seen online, from $50 a vial to $1,500 a month, was made up by someone selling it, guessing at it, or selling something else and calling it retatrutide.

Here's where each of those numbers comes from, what the closest approved drugs actually cost, and why "price per vial" is the wrong way to do the math.

Status as of October 21, 2026: retatrutide is not approved by any regulator in the world. Lilly plans to file with the FDA in Q1 2027. The only legal ways to get it in the US are Lilly's clinical trials and its expanded access program. FDA says it cannot be compounded. Nothing below is dosing or buying advice.

No. Lilly hasn't announced one, and it can't sell a drug that isn't approved.

Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027, once it finishes the manufacturing package for its application (Lilly, July 23, 2026). After a filing comes the FDA review. Only after approval does a list price exist. I searched for any Lilly statement on what it will charge and found none.

So when a site says retatrutide "will cost $1,000 to $1,500 a month," that's a guess built off tirzepatide's price. It might turn out close. It isn't a price.

Four places, and none of them is Lilly.

Expanded access. This is the one legal route outside a trial, and it costs nothing. But it's narrow: adults with a BMI of 35 or more despite sticking with treatment, two or more serious obesity-related complications, and no way to join a trial. Your doctor has to request it from Lilly (Lilly Medical, reviewed Aug 26, 2026).

Clinic bundles. These are real businesses with real prices, which is why they show up in search. At least 17 Georgia medical facilities, including med spas, wellness and weight-loss clinics, have advertised or promoted products marketed as retatrutide, according to an Atlanta Journal-Constitution investigation (Inc., Oct 19, 2026). A clinic price includes the visit, the markup and the clinic's legal risk. It tells you nothing about what retatrutide will cost.

"Compounded" offers. FDA's position is short: "Retatrutide and cagrilintide cannot be used in compounding under federal law" (FDA, updated Oct 1, 2026). Any "compounded retatrutide" price is a price for something no pharmacy is allowed to make. Where every peptide stands on that is on the compounding status tracker.

Research vials. This is where the cheap numbers come from. Reporting on the gray market has described GLP-1 powders, retatrutide among them, sold "for as little as $50 a vial" (Benzinga via Yahoo Finance, July 23, 2025). JAMA put it more broadly this month: black-market retatrutide products "generally cost less than the approved GLP-1 RAs" (JAMA, Oct 9, 2026). Treat any figure here as an unverified market listing. Nobody audits these prices, and as you'll see below, nobody audits what's in the vial either. The headline of that JAMA piece says the rest: these products are "No Bargain."

Legally, $0 through expanded access if you qualify, and nothing otherwise, because there is nothing legal to buy.

Every "per month" figure online is one of the four sources above, multiplied out by whoever wrote it. The monthly number depends on the dose they assumed, the vial price they assumed, and whether the vial holds what the label says. Change any one of those and the monthly cost moves a lot. That's the next section.

Because a vial isn't a month, and a "10 mg" label isn't a measurement.

Start with the first problem. The phase 3 trials started people at 2 mg once a week and stepped up every 4 weeks: 2, 4, 6, 9, then 12 mg (Lilly, July 23, 2026). Here's what that schedule means for how much a "10 mg" label covers. This is arithmetic on the trial doses, not a recommendation:

So the same vial price can mean very different monthly costs. Someone quoting "one vial a month" is quoting the first step of the trial schedule. At the top dose the trials tested, the same math needs almost five times as much.

Now the second problem: the label. University of Queensland researchers tested three products sold in Australia as 10 mg retatrutide. All three contained retatrutide, "but not the amount specified." One had only half of what the label said. The other two had more (JAMA, Oct 9, 2026, describing Drug and Alcohol Review, 2026). If a vial holds half its label, the real cost per milligram is double the sticker. If it holds more, you're getting a different dose than you think.

And sometimes it isn't retatrutide at all. Australia's drug regulator tested a product sold as retatrutide after a serious adverse event and found it "actually contained a high dose of semaglutide and no retatrutide" (JAMA, same article). A BMJ Case Reports paper this month described a woman in her twenties with five days of vomiting that three anti-nausea drugs couldn't stop, after injections of a product sold to her as retatrutide by a "life coach" (BMJ Case Reports, Oct 7, 2026). Nobody knows what she injected.

A cheap price per vial only means something if you know the milligrams and the molecule. Why that's so hard to know is covered in what a lab found in 6,441 vials and how to read a COA.

This is the best real-world anchor, because these are approved drugs with published self-pay prices. I checked both companies' own pricing pages on October 21, 2026.

Sources: LillyDirect Zepbound and NovoCare Wegovy, both read October 21, 2026.

Two catches on Zepbound. The $449 price for 7.5 mg and up depends on refilling within 45 days. Miss that window and Lilly lists regular prices of $499 for 7.5 mg and $699 for 10, 12.5 and 15 mg. And the 2.5 mg starting dose is, in Lilly's words, "not approved as a maintenance dose," so $299 is a starting price, not a long-term one. Both companies say they can change these programs at any time.

Will retatrutide land near these prices? Nobody knows. Lilly hasn't said. What these numbers do tell you is what a legal, labeled, inspected GLP-1 costs a self-paying adult in the US today: roughly $149 to $699 a month, depending on drug, form and dose.

No. There's nothing for an insurer to cover.

Insurance pays for approved drugs on a plan's list. Retatrutide isn't approved, so it can't be on any list. If a clinic tells you it "works with insurance" for retatrutide, ask what exactly is being billed. It may be the visit. It isn't the drug.

After approval, coverage will depend on your plan, like every other weight-loss drug. That's a 2027 question at the earliest.

Not outside trials and expanded access. Lilly's own line is that anything sold to consumers outside its trials "is illegal, with no way to verify its safety, purity, or dosing" (quoted by Inc., Oct 19, 2026).

Lilly is backing that up in court. On August 12 it sued six sellers, including a California med spa and a Texas compounding pharmacy (CBS News, Aug 12, 2026). On October 8 it filed five more, against three online retailers, a weight-loss clinic and a med spa, alleging the retailers use "research use only" disclaimers "to disguise sales of products intended for human use" (Buchanan Ingersoll & Rooney, Oct 15, 2026). That's eleven suits since August. They're allegations; none has been decided. All eleven are broken down here.

Lilly's own explanation for why people buy anyway, per CBS: "purported lower costs." Which brings it back to price.

I've been on retatrutide since July, and I wrote up the first month. So I'm not writing this from a high horse. I'm writing it because I went looking for a straight answer on cost and found a wall of sites selling the answer they wanted you to hear.

The straight answer: there is no price. There's a free program for a small group of very sick patients, a set of businesses getting sued, and a market where the label on the vial may or may not match what's inside. If you want a real number to plan around, Zepbound and Wegovy self-pay prices are the closest thing that exists, and they're published by the companies that make them.

If you're also trying to figure out the switch from tirzepatide, I covered what the trials did and didn't test.

Reply and tell me: what were you quoted for retatrutide, and by whom (a clinic, a telehealth company, a vial seller)? Don't send me names. Send me the shape of the offer. If enough of you write back, I'll publish what the market actually looks like, which is more than any of the price guides ranking for this search have done.